Search
Filter Results
Displaying 1–10 of 148 for “wet amd”
-
Oct 10, 2019
FDA Approves New Wet AMD Treatment that can be Administered Every Three Months
Beovu from Novartis reduces treatment burden for wet AMD patients
-
Oct 25, 2021
FDA Approves Genentech’s Susvimo for Treating Wet AMD
The approach significantly reduces the need for regular ocular injections.
-
Jan 26, 2021
Genentech’s Faricimab Performs Well in Phase 3 Clinical Trials for Wet AMD
Company will seek marketing approval for the emerging therapy
-
Feb 1, 2022
Genentech-Roche Receives FDA Approval for Vabysmo for Treatment of Wet AMD and DME
This new treatment can reduce the frequency of injections into the eye
-
May 28, 2020
Genentech’s Port Delivery System for Wet AMD Meets Primary Endpoint in Phase 3 Clinical Trial
Tiny implant provides continual delivery of anti-VEGF treatment for six months
-
May 15, 2020
Positive Interim Clinical Trial Results for Adverum’s Wet AMD Gene Therapy
The gene therapy is designed to reduce the treatment burden for patients
-
Mar 27, 2018
Vision Improvements Reported in Early Stem Cell Trial for Wet AMD
Two patients with advanced wet age-related macular degeneration (AMD) in a Phase I clinical trial demonstrated improved visual acuity sustained for one year after a sheet of retinal pigment epithelial (RPE) cells derived from embryonic stem cells was transplanted under their retinas. Each patient had one eye treated. Vision improvement for one patient was 29 letters or about 6 lines on an eye chart. The other had a gain of 21 letters or about 4 lines.
-
Aug 22, 2023
FDA Approves 8 MG Dosing of Eylea for Wet AMD, Diabetic Macular Edema, and Diabetic Retinopathy
New, higher treatment dose reduces frequency of eye injections for patients
-
Jan 7, 2021
REGENXBIO’s Wet AMD Gene Therapy Moving into Phase 3 Trials
In a Phase ½ clinical trial, the emerging treatment reduced the burden of regular anti-VEGF injections
-
Apr 30, 2019
REGENXBIO’s Gene Therapy for Wet AMD Performing Encouragingly in Human Study
Unlike current treatments requiring multiple injections, REGENXBIO’s gene therapy is administered as a one-time subretinal injection to the affected eye.